The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase III trial of dovitinib (TKI258) versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies.
Robert John Motzer
Consultant or Advisory Role - Pfizer
Research Funding - AVEO; GlaxoSmithKline; Novartis
Camillo Porta
Consultant or Advisory Role - Bayer Schering Pharma; GlaxoSmithKline; Novartis; Pfizer; Roche
Honoraria - Bayer Schering Pharma; GlaxoSmithKline; Novartis; Pfizer; Roche
Research Funding - Bayer Schering Pharma; Novartis
Georg A. Bjarnason
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Other Remuneration - Novartis
Cezary Szcylik
Consultant or Advisory Role - Novartis
Sun Young Rha
No relevant relationships to disclose
Emilio Esteban
No relevant relationships to disclose
Ugo De Giorgi
No relevant relationships to disclose
Mary J. MacKenzie
Honoraria - Novartis
Paul N. Mainwaring
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Other Remuneration - Novartis
Scott North
Honoraria - Novartis
Roberto Sabbatini
Consultant or Advisory Role - Bayer Schering Pharma; GlaxoSmithKline; Novartis; Pfizer; Roche
Honoraria - Bayer Schering Pharma; GlaxoSmithKline; Novartis; Pfizer; Roche
Istvan Bodrogi
No relevant relationships to disclose
Fairooz Kabbinavar
No relevant relationships to disclose
Giacomo Carteni
No relevant relationships to disclose
Cora N. Sternberg
Honoraria - GlaxoSmithKline; Novartis; Pfizer
Nicholas J. Vogelzang
Employment or Leadership Position - US Oncology
Consultant or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Celgene; Clinical Care Options; Cougar Biotechnology; Dendreon; Eisai; Genentech; GlaxoSmithKline; Johnson & Johnson; Novartis; Pfizer; Takeda; US Oncology; Veridex
Honoraria - ArQule; Bayer; Clinical Care Options; Cougar Biotechnology; Dendreon; Genentech; Johnson & Johnson; Lilly; Novartis; Pfizer; Sanofi ; US Oncology; Veridex; Wilex
Research Funding - Algeta; ArQule; Cougar Biotechnology; GlaxoSmithKline; Johnson & Johnson; Novartis; Pfizer; Takeda; Tokai; US Oncology; Veridex; Wilex
Michael Shi
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Gladys Urbanowitz
Employment or Leadership Position - Novartis
Bernard J. Escudier
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer